Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Trump-Backed American Bitcoin Corp (ABTC) Q3 2025 Earnings: Revenue Jumps 453% as BTC Hoard Tops 4,000, But Stock Whipsaws on Bitcoin Crash

Trump-Backed American Bitcoin Corp (ABTC) Q3 2025 Earnings: Revenue Jumps 453% as BTC Hoard Tops 4,000, But Stock Whipsaws on Bitcoin Crash

Trump-linked Bitcoin miner American Bitcoin Corp (Nasdaq: ABTC) has just posted its first quarterly profit as a public company, with Q3 2025 revenue surging to $64.2 million and its Bitcoin reserve climbing above 4,000 BTC. Yet despite the blockbuster numbers, ABTC shares swung sharply lower in early trading as Bitcoin itself tumbled below $95,000 in a violent crypto sell-off. PR Newswire+2Finviz+2 Key takeaways Q3 2025: Revenue explosion and a clean swing to profit American Bitcoin’s Q3 2025 report, released before the opening bell, marks a dramatic scaling-up in both size and profitability. PR Newswire+1 According to the company’s Form 10‑Q
14 November 2025
····
Cytek Biosciences (CTKB) Stock Pops in Choppy Market After String of Positive Catalysts – November 14, 2025

Cytek Biosciences (CTKB) Stock Pops in Choppy Market After String of Positive Catalysts – November 14, 2025

On Friday, November 14, 2025, Cytek Biosciences, Inc. (NASDAQ: CTKB) is trading sharply higher, extending a strong two‑week run helped by fresh industry recognition, product awards and steady (if modest) earnings growth. As of the latest trade this afternoon, CTKB is changing hands around $4.99, up roughly 9% intraday, with the stock appearing on Nasdaq’s list of notable movers even as the broader U.S. market trades lower.Benzinga Below is a breakdown of all the key Cytek‑related news impacting CTKB today, November 14, 2025, plus the most important headlines from the past few days that are driving sentiment. 1. What’s New
14 November 2025
····
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock Holding Corporation (NASDAQ: SRRK) is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market (ATM) stock offering. SRRK stock jumps over 25% after FDA “constructive” meeting Scholar Rock shares are surging today. As of the latest trade, SRRK is changing hands around $37.98, up roughly 26% on the session, after touching an intraday high above $39. Daily trading volume has climbed to about 2.75 million shares, well above normal levels. The move is being
14 November 2025
·····
StubHub Holdings (STUB) Crashes Over 25% After First Earnings as Public Company – What’s Really Going On?

StubHub Holdings (STUB) Crashes Over 25% After First Earnings as Public Company – What’s Really Going On?

StubHub Holdings (NYSE: STUB) shares plunged more than 25% today after the ticket marketplace’s first earnings report as a public company, a deep GAAP loss and a wave of Wall Street price‑target cuts. Here’s what the Q3 2025 numbers and analyst reactions mean for investors. Key Takeaways StubHub’s First Quarter as a Public Company: Growth on the Platform, Noise in the P&L StubHub’s Q3 2025 report is its first full earnings release since going public on the NYSE in September. The headline numbers show a marketplace that’s still growing: On an adjusted basis, StubHub is clearly trending the right way:
14 November 2025
···
Netflix’s 10-for-1 Stock Split Arrives Monday: What NFLX Investors Need to Know Today – and Why Eli Lilly Could Be Next

Netflix’s 10-for-1 Stock Split Arrives Monday: What NFLX Investors Need to Know Today – and Why Eli Lilly Could Be Next

Netflix’s long-awaited 10‑for‑1 stock split is now entering its crucial final stage. After today’s market close, existing shareholders will receive nine additional shares for every one they already own, with split‑adjusted trading set to begin on Monday, November 17.Netflix+2Nasdaq+2 At the same time, Wall Street is buzzing about Eli Lilly (LLY), whose four‑digit share price and explosive growth have many analysts suggesting it could be the next mega‑cap stock to announce a split.Appreciate Wealth+3Barron’s+3Barron’s+3 Key Takeaways for November 14, 2025 Netflix’s 10‑for‑1 Stock Split: The Essential Facts Netflix’s Board approved a 10‑for‑1 forward stock split on October 30, 2025. The
14 November 2025
····
Light & Wonder (ASX:LNW) Completes Nasdaq Delisting, Fires Up A$10.8bn ASX Era With New Mega Buyback

Light & Wonder (ASX:LNW) Completes Nasdaq Delisting, Fires Up A$10.8bn ASX Era With New Mega Buyback

Light & Wonder, Inc. has officially left the Nasdaq and begun life as a sole listing on the Australian Securities Exchange (ASX), wrapping the move in a suite of shareholder‑friendly measures – including a huge new on‑market buyback, fresh governance documents, and an updated employee stock purchase plan effective today. IAG+2LNW Explore+2 At the close in Sydney, Light & Wonder’s CHESS Depositary Interests (CDIs) were trading around A$131.66, down about 2% on the day, valuing the cross‑platform gaming group at roughly A$10.8 billion (US$7.0 billion). GuruFocus+2Investing.com+2 Sole ASX listing now live after Nasdaq exit Light & Wonder’s transition from a
14 November 2025
···
Ondas Holdings (ONDS) Surges as Oppenheimer Upgrade Caps Record Q3 2025 Rally

Ondas Holdings (ONDS) Surges as Oppenheimer Upgrade Caps Record Q3 2025 Rally

Ondas Holdings is back in the spotlight on Friday after a week of record financial results, aggressive guidance, and a fresh Wall Street upgrade that’s pushed the drone and defense technology stock sharply higher. Shares of Ondas climbed more than 19% on Thursday to close at $6.56, after the company reported Q3 2025 revenue of $10.1 million, a more than fivefold year‑over‑year jump, and raised its full‑year outlook. Finviz+2Stock Titan+2 By Friday morning, the rally continued: ONDS was recently trading around the mid‑$7 range, up roughly 10–13% over the last 24 hours, giving the company a market capitalization of about
14 November 2025
··
Opendoor (OPEN) Stock News Today – AI Pivot, $1M CEO Buy and Q3 Earnings Put Meme Favorite Back Under the Microscope

Opendoor (OPEN) Stock News Today – AI Pivot, $1M CEO Buy and Q3 Earnings Put Meme Favorite Back Under the Microscope

Opendoor Technologies Inc. (OPEN) is back in the market spotlight today as a flood of fresh coverage dissects its high‑stakes AI pivot, a $1 million insider stock purchase, and the lingering fallout from weak third‑quarter results — all against the backdrop of a meme‑fueled rally that has sent the stock from penny‑stock territory to around $8–9 a share this year. Google+2TradingView+2 Opendoor share price snapshot on 14 November 2025 That surge has turned Opendoor into one of 2025’s most talked‑about meme stocks — but today’s news coverage shows just how divided opinion remains on whether the ride can continue. 24/7
14 November 2025
··
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight today after the company and its partner Johnson & Johnson announced they will discontinue a major Phase 3 trial of their experimental blood thinner milvexian in acute coronary syndrome (ACS). The decision, based on a scheduled interim review showing the study was unlikely to hit its main goal, has pushed BMY shares lower and reignited
14 November 2025
······
Applied Digital (APLD) Prices $2.35 Billion Notes as AI Data Center Expansion Meets Market Jitters

Applied Digital (APLD) Prices $2.35 Billion Notes as AI Data Center Expansion Meets Market Jitters

Applied Digital Corporation (NASDAQ: APLD), one of the fastest‑growing AI data‑center names on the Nasdaq, is back in focus today after pricing a massive $2.35 billion senior secured notes offering designed to supercharge its North Dakota “AI Factory” buildout. The financing arrives just days after the company lined up up to $787.5 million in additional equity funding from Macquarie Asset Management, but the stock is still suffering one of its roughest weeks in nearly two years as investors weigh leverage, dilution and broader AI anxiety. Applied Digital Corporation+2Applied Digital Corporation+2 Key headlines for Applied Digital on November 14, 2025 1.
14 November 2025
···
TSS Inc. (TSSI) Stock Plunges Over 40% After Q3 2025 Earnings – AI Pivot, New Dell Veteran Director and What’s Next for 2026

TSS Inc. (TSSI) Stock Plunges Over 40% After Q3 2025 Earnings – AI Pivot, New Dell Veteran Director and What’s Next for 2026

TSS, Inc. (NASDAQ: TSSI), the AI‑focused data center systems integrator, is at the center of a dramatic market move today. Shares are trading in the high single digits this afternoon, down a little over 40% from yesterday’s close around $15.25, after investors digested a sharp Q3 2025 revenue decline, a swing to loss, and a simultaneously raised full‑year profit outlook. Finimize At the same time, TSS has deepened its AI ambitions by appointing Dell Technologies veteran Vivek Mohindra to its board of directors, drawing a wave of fresh analysis from Wall Street and independent research platforms. Stock Titan+1 Below is
14 November 2025
·····
Akanda Corp. (AKAN) Today: Full Cultivation License Push, Telecom Growth and Stock Reaction – November 14, 2025

Akanda Corp. (AKAN) Today: Full Cultivation License Push, Telecom Growth and Stock Reaction – November 14, 2025

Akanda Corp. (NASDAQ: AKAN) is back in the news today after outlining the next steps toward a full Health Canada cultivation license at its British Columbia cannabis site, while commentators highlight the company’s unusual mix of Mexican telecom infrastructure and Canadian cannabis “optionality.” Newsfile+1 A fresh Newsfile press release this morning details how Akanda will design and implement Health Canada–compliant security at its Gabriola Island facility, a prerequisite for producing THC- and CBD-rich cannabis under a full cultivation license. Newsfile+1 At the same time, a new MarketScreener feature frames Akanda as a “dual‑track” small cap: cash flow from towers and
14 November 2025
·
1 … 42 43 44 45 46 … 233

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Go toTop